About altimmune inc. - ALT
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
ALT At a Glance
Altimmune, Inc.
910 Clopper Road
Gaithersburg, Maryland 20878
| Phone | 1-240-654-1450 | Revenue | 20.00K | |
| Industry | Biotechnology | Net Income | -95,059,000.00 | |
| Sector | Health Technology | Employees | 59 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ALT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 25,596.725 |
| Price to Book Ratio | 4.224 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.708 |
| Enterprise Value to Sales | 19,084.125 |
| Total Debt to Enterprise Value | 0.004 |
ALT Efficiency
| Revenue/Employee | 338.983 |
| Income Per Employee | -1,611,169.492 |
| Receivables Turnover | 0.006 |
| Total Asset Turnover | 0.00 |
ALT Liquidity
| Current Ratio | 13.102 |
| Quick Ratio | 13.102 |
| Cash Ratio | 12.603 |
ALT Profitability
| Gross Margin | -1,090.00 |
| Operating Margin | -515,860.00 |
| Pretax Margin | -475,295.00 |
| Net Margin | -475,295.00 |
| Return on Assets | -54.328 |
| Return on Equity | -59.86 |
| Return on Total Capital | -75.932 |
| Return on Invested Capital | -59.564 |
ALT Capital Structure
| Total Debt to Total Equity | 1.361 |
| Total Debt to Total Capital | 1.343 |
| Total Debt to Total Assets | 1.207 |
| Long-Term Debt to Equity | 1.135 |
| Long-Term Debt to Total Capital | 1.12 |
Altimmune Inc. in the News
Next generation coronavirus vaccine in pill, spray forms could have these benefits, Dr. Nesheiwat explains
Fox News medical contributor Dr. Janette Nesheiwat broke down to "Kudlow" that a wider range of coronavirus vaccine options would be beneficial for pandemic recovery as well as personal health.